Which groups of people are not suitable for taking Eltrombopag ethanolamine tablets (Revlan)?

Eltrombopag ethanolamine tablets (Eltrombopag) is a thrombopoietin receptor agonist, mainly used for patients with chronic immune thrombocytopenic purpura (ITP), aplastic anemia and chronic liver disease-related thrombocytopenia. Although its efficacy is significant, not all patients are suitable for use, and specific groups need to be cautious or disabled to avoid potential safety risks.

First of all, patients who are allergic to eltrombopag or drug excipients are not suitable for use. Such patients may experience severe allergic reactions such as rash, itching, difficulty breathing or facial swelling after taking it. Those with a clear history of allergy should choose alternative drugs under the guidance of a doctor to avoid serious adverse events caused by drug allergy.

Secondly, patients with severe liver dysfunction or active liver disease should use it with caution. Eltrombopag is mainly metabolized by the liver. Impaired liver function may lead to increased blood concentration and increase the risk of hepatotoxicity. For patients with significantly elevated liver enzymes or complications of cirrhosis, the risks and benefits should be evaluated under the premise of strict monitoring of liver function, and dose adjustment or medication suspension should be considered if necessary.

In addition, it should be used with caution in patients at risk for blood clots. Thrombopoietin receptor agonists may cause a significant increase in platelets and increase the risk of thrombotic events, such as deep vein thrombosis, pulmonary embolism, or cardiovascular and cerebrovascular events. Patients with a history of thrombosis or hypercoagulability should strictly monitor their platelet count under the guidance of a doctor and weigh the risks and benefits of treatment. The safety of pregnant and lactating women has not been fully established, and the decision whether to use it needs to be evaluated by a professional physician.

Reference materials:https://www.drugs.com/